Holen Sie sich die Stockscreener-App
18.49
28.94%
4.15
Handel nachbörslich:
19.30
0.81
+4.38%
Schlusskurs vom Vortag:
$14.34
Offen:
$15.17
24-Stunden-Volumen:
14.16M
Relative Volume:
4.48
Marktkapitalisierung:
$1.31B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-145.21M
KGV:
-8.0391
EPS:
-2.3
Netto-Cashflow:
$-140.12M
1W Leistung:
+54.73%
1M Leistung:
+27.08%
6M Leistung:
-61.70%
1J Leistung:
-61.62%
1-Tages-Spanne:
$14.92
$18.65
1-Wochen-Bereich:
$11.06
$18.65
52-Wochen-Spanne:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Firmenname
Moonlake Immunotherapeutics
Sektor
Branche
Telefon
41 41 510 8022
Adresse
DORFSTRASSE 29, ZUG
Vergleichen Sie MLTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
18.49 | 1.02B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-11-03 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-09-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-09-30 | Herabstufung | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2025-09-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | Herabstufung | Stifel | Buy → Hold |
| 2025-07-28 | Eingeleitet | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2024-11-05 | Fortgesetzt | Wedbush | Outperform |
| 2024-08-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-02 | Eingeleitet | Goldman | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-11-02 | Eingeleitet | Stifel | Buy |
| 2023-09-14 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | Eingeleitet | Needham | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Equal Weight |
| 2023-05-01 | Eingeleitet | Guggenheim | Buy |
| 2023-03-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-09 | Eingeleitet | BTIG Research | Buy |
| 2023-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-02 | Eingeleitet | Bryan Garnier | Buy |
| 2022-11-11 | Eingeleitet | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | SVB Leerink | Outperform |
| 2022-07-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Moonlake Immunotherapeutics Aktie (MLTX) Neueste Nachrichten
MoonLake Immunotherapeutics (MLTX) Valuation After FDA Clears Existing Data For Sonelokimab BLA In Hidradenitis Suppurativa - simplywall.st
MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations - Stocktwits
MoonLake Options Trading: A Deep Dive into Market Sentiment - Benzinga
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation - FinancialContent
Tranquility Restored For MoonLake With Positive FDA Feedback On HS Drug - Citeline News & Insights
MoonLake price target raised to $32 from $26 at H.C. Wainwright - TipRanks
MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission (NASDAQ:MLTX) - Seeking Alpha
MLTX Analyst Rating: HC Wainwright & Co. Raises Price Target to $32.00 | MLTX Stock News - GuruFocus
BTIG Upgrades MoonLake Immunotherapeutics (MLTX) - Nasdaq
Moonlake Immunotherapeutics stock upgraded to Buy at BTIG on FDA feedback - Investing.com Nigeria
Will MoonLake's Clinical Milestones Send Investors Over The Moon? - RTTNews
Will MoonLake Immunotherapeutics stock benefit from AI adoptionJuly 2025 Update & High Conviction Trade Alerts - ulpravda.ru
MoonLake Immunotherapeutics stock price target raised to $45 by Clear Street By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics (MLTX) Is Up 20.0% After FDA Clears Existing SLK Data For HS BLA Path - Yahoo Finance
What margin trends mean for MoonLake Immunotherapeutics stockQuarterly Trade Review & High Conviction Investment Ideas - ulpravda.ru
Will MoonLake Immunotherapeutics stock reach all time highs in 2025CEO Change & Growth Focused Entry Reports - ulpravda.ru
Will MoonLake Immunotherapeutics stock benefit from sector rotationWeekly Gains Summary & Low Drawdown Momentum Trade Ideas - ulpravda.ru
MoonLake Immunotherapeutics Stock Collapses. Why It’s Down 88%. - MSN
Biopharma bites: A flurry of financings headlined by Diagonal, plus updates from Servier, MoonLake - FirstWord
MoonLake stock jumps after FDA feedback clears path for sonelokimab filing without new HS trials - TechStock²
Will MoonLake Immunotherapeutics stock rally after Fed decisionsMarket Sentiment Report & Consistent Profit Trading Strategies - ulpravda.ru
Why MoonLake Immunotherapeutics stock could rally in 20252025 Top Gainers & Safe Investment Capital Preservation Plans - ulpravda.ru
MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating - TipRanks
Biotech Soars 27% On FDA Deal For Beleaguered Skin Drug - Investor's Business Daily
MoonLake soars 45% after FDA clears path for key skin drug | Tap to know more | Inshorts - Inshorts
MLTX Surge: Will The Momentum Last? - StocksToTrade
What is the fair value of MoonLake Immunotherapeutics stock nowMarket Growth Review & Technical Entry and Exit Tips - ulpravda.ru
MoonLake States FDA Might Permit Skin Medication Submission Without Additional Studies, Shares Surge - Bitget
MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars - Benzinga
MoonLake revives FDA push; Biotech trio to debut in Hong Kong - Endpoints News
De-Risked HS Pathway and Expanding PsA Optionality Underpin Buy Rating on MoonLake and Top-Idea Status for 2026 - TipRanks
Can MoonLake Immunotherapeutics stock hit record highs again2025 Earnings Impact & Risk Controlled Swing Trade Alerts - ulpravda.ru
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $34 - 富途牛牛
MoonLake Immunotherapeutics stock price target raised to $45 by Clear Street - Investing.com South Africa
MoonLake (MLTX): De-Risked HS Pathway and Multi-Indication Pipeline Support Attractive Risk/Reward and Buy Rating - TipRanks
MoonLake Immunotherapeutics Shares Rise on FDA Alignment to File Application Without New Trials - MarketScreener
MoonLake provides update following positive feedback from U.S. FDA for SLK - TipRanks
Clear Street Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $45 - 富途牛牛
MLTX Stocks: Is the Price Right? - timothysykes.com
Why Did MLTX Stock Jump 45% In Pre-Market Today? - Stocktwits
MoonLake Immunotherapeutics price target raised to $45 from $12 at Clear Street - TipRanks
MoonLake Advances Sonelokimab After Positive FDA Feedback - TipRanks
Moonlake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. Fda - MarketScreener
FDA confirms MoonLake’s path to HS drug approval without additional trials - Investing.com
FDA confirms MoonLake’s path to HS drug approval without additional trials By Investing.com - Investing.com South Africa
MoonLake lead drug needs no additional trials (MLTX:NASDAQ) - Seeking Alpha
MoonLake stock soars after FDA feedback on HS treatment path By Investing.com - Investing.com South Africa
MoonLake stock soars after FDA feedback on HS treatment path - Investing.com
MoonLake Immunotherapeutics Announces Positive FDA Feedback on SLK - TradingView — Track All Markets
MoonLake Immunotherapeutics Announces Positive Outcome from - GlobeNewswire
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG - TipRanks
Finanzdaten der Moonlake Immunotherapeutics-Aktie (MLTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moonlake Immunotherapeutics-Aktie (MLTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | Chief Executive Officer |
Dec 09 '25 |
Sale |
14.49 |
70,000 |
1,014,300 |
2,878,577 |
| Reich Kristian | Chief Scientific Officer |
Dec 08 '25 |
Sale |
15.08 |
130,000 |
1,960,400 |
72,908 |
| Reich Kristian | Chief Scientific Officer |
Dec 09 '25 |
Sale |
14.43 |
72,908 |
1,052,062 |
0 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):